ASH 2022 | Long-term follow-up results from the RATHL trial: response-adapted treatment for advanced stage HL

Stefano Luminari, MD, University of Modena and Reggio Emilia, Modena, Italy, presents seven-year follow-up results from the RATHL trial (CRUK/07/033), which assessed the use of FDG PET-CT scans in guiding the subsequent treatment of patients with advanced stage Hodgkin lymphoma (HL). In this trial, patients with positive scans following two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy proceeded to intensification with BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and patients with negative scans were randomized to ABVD or AVD. Results demonstrated that intensification with BEACOPP is safe and effective, with no evidence of an increase in secondary malignancies in this group. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.